Voltar
Revisão Acesso aberto Revisado por pares
BIBTEX RIS

Monoclonal antibodies in MS

2009; Lippincott Williams & Wilkins; Volume: 74; Issue: 1_supplement_1 Linguagem: Inglês

10.1212/wnl.0b013e3181c97ed3

ISSN

1526-632X

Autores

Bibiana Bielekova, Brenda L. Becker,

Tópico(s)

Multiple Sclerosis Research Studies

Resumo

The development of monoclonal antibodies (mAbs) presents an emerging, highly specific therapeutic strategy for the treatment of multiple sclerosis (MS). mAbs target selective molecules and have shown early promise, along with notable risks, in the treatment of MS and other immune-mediated diseases. The mechanism of action of the 4 mAbs under active investigation for MS (natalizumab, rituximab, alemtuzumab, and daclizumab) are reviewed, with a discussion of how mAb interaction with each target antigen may produce direct and indirect effects (proven and hypothesized) on immune cell activity, CNS-related inflammatory processes, and clinical outcomes.

Referência(s)